AIM — AIM ImmunoTech Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 946644 ·
Last close
$0.23
Market Cap
$3.39M
52W High
$1.62
52W Low
$0.21
ADV30
17,801,030
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 22,000 | 18,000 | -2,226,000 | -3,023,000 | 8,585,000 | 5,816,000 | 6,460,000 |
| Dec 2025 | 21,000 | -19,000 | -2,952,000 | -4,175,000 | 5,782,000 | 2,985,000 | 15,565,000 |
| Sep 2025 | 26,000 | -42,000 | -2,447,000 | -3,284,000 | 5,494,000 | 2,347,000 | 11,571,000 |
| Jun 2025 | 25,000 | 15,000 | -2,646,000 | -2,794,000 | 4,129,000 | 476,000 | 10,675,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,957,000
Investing CF
$1,853,000
Financing CF
$10,388,000
CapEx
$-497,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-16.23
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-440,786,000
Inventory
—
Receivables
$7,000
ST Investments
$62,000
EBIT TTM
$-13,146,000
Pretax Income TTM
$-13,958,000
Interest Exp TTM
$812,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$88,000
EBITDA
$-11,454,000
Free Cash Flow
$-11,966,500
Enterprise Value
$3,910,388
Total Cash
$3,047,000
Total Debt
$4,896,000
Shares Out
14,563,515
Trailing EPS
$-4.31
Book Value
$-3.19
ROE
—
ROA
-101.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 88,000 | -11,664,000 | -13,958,000 | 5,782,000 | 15,565,000 | — | -10,957,000 |
| Dec 2024 | 170,000 | -19,772,000 | -17,320,000 | 8,608,000 | 9,930,000 | — | -14,888,000 |
| Dec 2023 | 202,000 | -31,916,000 | -28,962,000 | 19,381,000 | 9,147,000 | — | -21,267,000 |
| Dec 2022 | 141,000 | -19,923,000 | -19,445,000 | 40,488,000 | 2,020,000 | — | -16,108,000 |
TTM Snapshot
Revenues TTM
$120,000
NetIncome TTM
$-15,925,000
OpCashFlow TTM
$0
Assets (Latest)
$29,440,000
Forward EPS
$-1.47
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLDI | Calidi Biotherapeutics, Inc. | $3.42M | $0.18 | — |
| VIVS | VivoSim Labs, INC. | $3.73M | $1.29 | — |
| APTOF | Aptose Biosciences Inc. | $4.29M | $1.68 | — |
| CPMV | Mosaic ImmunoEngineering Inc. | $5.03M | $0.69 | — |
| SCNI | Scinai Immunotherapeutics Ltd. | $1.91M | $0.48 | — |
News headlines (Yahoo Finance, 1h cache)
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
2026-05-20 19:02 · Yahoo
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Prior
2026-05-19 12:02 · Yahoo
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
2026-05-14 12:41 · Yahoo
Transcript: Aimia Q1 2026 Earnings Conference Call
2026-05-13 13:47 · Yahoo
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
2026-05-08 12:40 · Yahoo
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
2026-05-07 12:23 · Yahoo
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
2026-04-16 13:00 · Yahoo
AIM ImmunoTech Provides Routine Update on Annual Filings
2026-04-13 22:00 · Yahoo
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
2026-04-09 12:00 · Yahoo
AIMIA PROVIDES UPDATE ON ITS SHARE BUYBACKS
2026-04-01 13:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.